Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Mendus AB

Market Cap 344M 36.64M 31.57M 29.07M 27.3M 51.25M 3.46B 51.79M 134M 1.7B 137M 135M 5.88B P/E Ratio 2026 *
-3.48x
P/E Ratio 2027 * -5.92x
Enterprise Value 22.25M 2.37M 2.05M 1.88M 1.77M 3.32M 224M 3.35M 8.67M 110M 8.91M 8.72M 381M EV / Sales 2026 *
2.49x
EV / Sales 2027 * 0.65x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day+5.26%
1 week+11.78%
Current month-1.58%
1 month-5.08%
3 months+34.62%
6 months+12.34%
1 week 5
Extreme 5
5.67
1 month 4.9
Extreme 4.9
6
Current year 3.86
Extreme 3.86
6.9
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 15/03/2021
Chief Executive Officer 76 12/12/2019
Director of Finance/CFO 60 27/02/2021
Director TitleAgeSince
Chairman 52 21/01/2021
Director/Board Member 64 31/12/2019
Director/Board Member 74 31/12/2012
Date Insider Type Main position Quantity % Market Cap.
27/02/22Buy

Chief Technology Officer

10,000 0.0050%
23/02/22Buy

Chief Executive Officer

84,000 0.0421%
23/02/22Buy

Chief Financial Officer

20,000 0.0100%
Change 5-day change 1-year change 3-year change Capi.($)
+5.26%+11.78%-12.77%-53.18% 34.8M
-0.12%+1.04%-13.08%-12.43% 43.58B
-2.17%+5.45%+285.76%+522.83% 34.03B
+0.44%-2.46%+14.20%-17.35% 29.77B
-1.60%-2.54%-2.12%+31.28% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
+3.54%+12.34% - - 13.87B
-1.26%+0.81%+54.77%+109.24% 13.35B
-1.04%-3.33%+3.98%+3.91% 12.85B
-1.18%-0.61%+105.37%+75.32% 12.22B
Average +0.20%+2.44%+50.01%+75.73% 21.5B
Weighted average by Cap. -0.49%+2.02%+59.37%+102.69%

Financials

2026 *2027 *
Net sales 8.95M 954K 823K 757K 711K 1.34M 90.24M 1.35M 3.49M 44.19M 3.58M 3.51M 153M 224M 23.94M 20.63M 19M 17.84M 33.49M 2.26B 33.84M 87.46M 1.11B 89.85M 87.94M 3.84B
Net income -163M -17.38M -14.98M -13.79M -12.95M -24.31M -1.64B -24.57M -63.49M -805M -65.22M -63.84M -2.79B -18.59M -1.98M -1.71M -1.57M -1.48M -2.77M -187M -2.8M -7.24M -91.78M -7.44M -7.28M -318M
Net Debt -321M -34.26M -29.53M -27.19M -25.53M -47.93M -3.24B -48.44M -125M -1.59B -129M -126M -5.5B -197M -21.01M -18.11M -16.67M -15.65M -29.39M -1.99B -29.7M -76.75M -973M -78.84M -77.17M -3.37B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
27
Date Price Change Volume
16/06/26 5.600 kr +5.26% 36,083
15/06/26 5.320 kr +4.31% 40,679
12/06/26 5.100 kr -1.35% 6,477
11/06/26 5.170 kr -0.19% 10,712
10/06/26 5.180 kr +1.57% 11,476
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.320SEK
Average target price
16.00SEK
Spread / Average Target
+200.75%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!